Skip to main content

Table 1 Baseline patient and tumor characteristics

From: Usefulness of Serum Carcinoembryonic Antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study

N = 180   Mean ± SD Patients n (%)
Age (years)   59.4 ± 12.2   
Gender Women   82 (45.6)
Men   98 (54.4)
Smoking History Positive   103 (57.3)
Negative   77 (42.7)
Wood-smoke exposure Positive   73 (40.6)
Negative   103 (59.4)
ECOG 0   38 21.1)
1   115 (63.9)
2   26 (14.4)
3   1 (0.6)
Clinical Stage III   28 (15.6)
IV   152 (84.4)
Histology Adenocarcinoma   152 (84.4)
Squamous-cell   14 (7.8)
Undifferentiated   13 (7.2)
Large-cell carcinoma   1 (0.6)
Baseline CEA   242.8 ± 685   
Treatment Platinum-Based CT   168 (93.3)
Tyrosine-kinase    
inhibitors   12 (6.7)
Tumor ResponseEvaluation Complete/Partial   51 (28.3)
Stable Disease   89 (49.4)
  Progressive Disease   40 (22.2)
  1. Abbreviations: SD, standard deviation; CEA, carcinoembryonic antigen; CT, chemotherapy.